Metipranolol pp 126-131 | Cite as

Results of a Long-term Study with Metipranolol

  • W. Kruse
Conference paper


Since the introduction of pilocarpine in the treatment of glaucoma the topical application of beta-receptor blocking agents to the eye in order to reduce intraocular pressure has been the most radical change in glaucoma therapy. The various, for the patient often unpleasant disadvantages of treatment with miotics — loss of light due to contraction of pupils, myopisation and frequent instillation — no longer apply when beta-receptor blockers are used. During the last 3 months the beta-receptor blocker metipranolol (Betamann®) has been presented in 0.3% and 0.6% solutions as an effective alternative to timolol (Chibro-Timolol®), a beta-receptor blocker which has been widely used for some time. Today we wish to report on a long-term study which — after a pilot study had been conducted in the first 3 months of 1980 — was initiated in the second half of 1980 in our ophthalmological practice and is still being conducted.


Intraocular Pressure Complete Period Iridocorneal Angle Glaucoma Therapy Ophthalmological Practice 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Copyright information

© Springer-Verlag Wien 1984

Authors and Affiliations

  • W. Kruse
    • 1
  1. 1.Berlin 19Germany

Personalised recommendations